# US 2021/0228635 A1 · Therapeutic dosage regimens comprising adherent stromal cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228635 A1
- Document ID: US20210228635A1
- Status: Published application
- Kind: A1
- Application number: 15/734,605
- Filed: 2019-06-10
- Published: 2021-07-29
- Earliest claimed: 2018-06-11
- Assignees: Pluristem Ltd.
- Applicants: Pluristem Ltd.
- Inventors: Zami ABERMAN; Yaacob YANAY; Rachel OFIR; Marc TRITEL
- Web page: https://patentgrep.com/patent/US20210228635A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- C12N 2500/98: Xeno-free medium and culture conditions
- C12N 2513/00: 3D culture
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are pharmaceutical compositions and therapeutic dosage regimens comprising or utilizing adherent stromal cells. The adherent stromal cells may be derived e.g. from placental tissue, from adipose tissue, or from bone marrow. The pharmaceutical compositions may be indicated for treating various disorders, e.g. ischemic disorders, hematopoietic disorders, and neurodegenerative disorders, inflammatory disorders, and neoplasms. The pharmaceutical compositions may further include pharmacologically acceptable excipients.

## Claims

### Claim 1

A therapeutic method, comprising:
a. administering to a subject a first pharmaceutical composition, comprising allogeneic adherent stromal cells (ASC) from a first donor; and
b. administering to said subject, at least 7 days after step a), a second pharmaceutical composition comprising allogeneic ASC from a second donor, wherein said second donor differs from said first donor in at least one allele group of human leukocyte antigen (HLA)-A or human leukocyte antigen (HLA)-B.

### Claim 2 (depends on 1)

The therapeutic method of claim 1, wherein said second donor differs from said first donor in at least one allele group of HLA-A.

### Claim 3 (depends on 1)

The therapeutic method of claim 1, wherein said second donor differs from said first donor in at least one allele group of HLA-B.

### Claim 4 (depends on 1)

The therapeutic method of claim 1, wherein said second donor differs from said first donor in both allele groups of HLA-A or HLA-B.

### Claim 5 (depends on 1)

The therapeutic method of claim 1, wherein said second donor differs from said first donor in at least one allele supertype of HLA-A or HLA-B.

### Claim 6 (depends on 1)

The therapeutic method of claim 1, wherein said second donor differs from said first donor in both allele supertypes of HLA-A.

### Claim 7 (depends on 1)

The therapeutic method of claim 1, wherein step b) is performed between 2-52 weeks after step a).

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The therapeutic method of claim 1, wherein step b) is performed between 6-20 weeks after step a).

### Claim 10 (depends on 1)

The therapeutic method of claim 1, further comprising administering to said subject, at least 7 days after step b), a third pharmaceutical composition comprising allogeneic ASC of a third donor, wherein said third donor differs from both said first donor and said second donor in at least one allele group of HLA-A or HLA-B.

### Claim at position 11

11-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein said ASC originate from placenta tissue.

### Claim 23 (depends on 22)

The method of claim 22, wherein said ASC express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.

### Claim 24 (depends on 22)

The method of claim 22, wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD11b, CD14, CD19, and CD34.

### Claim 25 (depends on 22)

The method of claim 22, wherein said ASC do not express a marker selected from the group consisting of CD3, CD4, CD34, CD39, and CD106.

### Claim 26 (depends on 25)

The method of claim 25, wherein less than 50% of said ASC express CD200.

### Claim 27 (depends on 25)

The method of claim 25, wherein more than 50% of said ASC express CD200.

### Claim 28 (depends on 25)

The method of claim 25, wherein more than 50% of said ASC express CD141 or SSEA4.

### Claim 29 (depends on 25)

The method of claim 25, wherein more than 50% of said ASC express HLA-A2.

### Claim 30 (depends on 1)

The method of claim 1, wherein said ASC originate from adipose tissue or bone marrow.

### Claim 31 (depends on 1)

The method of claim 1, wherein the cells are administered intramuscularly.

### Claim 32 (depends on 1)

The method of claim 1, wherein the cells are administered intravenously, subcutaneously, or intraperitoneally.
